IM Therapeutics gets SBIR grant
BROOMFIELD — ImmunoMolecular Therapeutics LLC, or IM Therapeutics, a company developing small molecular therapies for patients with genetically defined autoimmune diseases, has been awarded a grant from the Small Business Innovation Research program.
The Broomfield-based company received the grant for its development of an oral small molecular drug for the preservation of residual beta cell function in type 1 diabetes. The treatment also got Rare Pediatric Disease designation from the U.S. Food and Drug Administration, which can help fast-track the process. The treatment is called D enantiomer of methyldopa, or D-MDOPA.
“The Rare Pediatric Disease designation and SBIR grant awarded to IM Therapeutics for D-MDOPA show the need for new treatment options for type 1 diabetes, a lifelong disease for which there are no approved therapies to treat the underlying autoimmunity,” Aaron Michels, chief scientific officer for IM Therapeutics, said in a prepared statement. The goal is to help maintain normal insulin production.
SPONSORED CONTENT
Commercial Solar is a big investment, but not an overwhelming one
Solar offers a significant economic benefit for commercial property owners while also positively impacting the environment and offering a path to compliance for new municipal requirements like Energize Denver. A local, experienced solar installer will help you navigate the complexities of commercial solar to achieve financial success for your project.
The SBIR grant will help support the development of the treatment and phase 1 studies. The grant amount was not disclosed.
BROOMFIELD — ImmunoMolecular Therapeutics LLC, or IM Therapeutics, a company developing small molecular therapies for patients with genetically defined autoimmune diseases, has been awarded a grant from the Small Business Innovation Research program.
The Broomfield-based company received the grant for its development of an oral small molecular drug for the preservation of residual beta cell function in type 1 diabetes. The treatment also got Rare Pediatric Disease designation from the U.S. Food and Drug Administration, which can help fast-track the process. The treatment is called D enantiomer of methyldopa, or D-MDOPA.
“The Rare…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!